Thomson Reuters today announced that drug information for clinicians in the UK and Italy is now available in its Micromedex® clinical reference solution.
The comprehensive content of Micromedex 2.0 is now coupled with the UK’s Electronic Medicines Compendium Summary of Product Characteristics (SPCs) and Dialogo sui Farmaci’s AIFA-approved Italian drug file.
Customers can search on commercial or generic drug names to access this new information.
The new content delivers UK-approved information on dose, therapeutic indications, possible side effects and more in the familiar, consistent Micromedex format.
The new Italian drug file delivers AIFA-approved indications and limitations, AIFA prescribing criteria such as form, dose, reimbursement class, price, route of administration and packaging, as well as information about off-patent drugs, MINSAN and ATC codes.
More than 3,500 hospitals and healthcare institutions in 85 countries rely on the rigorously researched, evidenced-based clinical information of Micromedex.
Inclusion of this information for the UK and Italy is part of an ongoing Micromedex development program to support local clinical decision-making around the world. The Micromedex 2.0 interface is available in nine languages.
“Micromedex has always represented an invaluable source of independent, reliable drug information,” said Prof. Achille P. Caputi, Director of the Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Italy.
“The new Micromedex 2.0 has provided a more intuitive search platform that will certainly make finding clinical information much faster and easier.
“More importantly, the opportunity to gather drug information in the national language will positively influence the search skills of a large proportion of Italian physicians, with substantial improvements also in the quality of prescribing.”